Skip to main content

Table 5 Event rates in patients with and without cancer

From: Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY

All patients Pts with cancer at admission Pts without cancer at admission OR (95%CI) p-value*
  n/avail. % n/avail. %   
Thromboembolic events       
   Combined endpoint 12/227 5.29 104/2516 4.13 1.29 (0.70-2.39) 0.4097
Proximal DVT 10/225 4.44 98/2516 3.90 1.15 (0.59-2.23) 0.6851
Symptomatic non-fatal PE 1/257 0.39 9/2827 0.32 1.22 (0.15-9.69) 0.8488
VTE related death 1/263 0.38 0/2852 0 - -
   Distal DVT 17/207 8.21 178/2270 7.84 1.05 (0.63-1.77) 0.8495
   Proximal or distal DVT 21/207 10.14 218/2280 9.56 1.07 (0.67-1.71) 0.7851
   Symptomatic DVT 2/253 0.79 7/2814 0.25 3.20 (0.66-15.46) 0.1488
   Death from any cause 8/263 3.04 33/2852 1.16 2.68 (1.22-5.86) 0.0136
  1. Legend: Pts, patients; UFH, unfractionated heparin; DVT, deep venous thrombosis; PE, pulmonary embolism; OR, odds ratio; CI, confidence interval, * two-sided p-value for null-hypothesis: difference = 0 or odds ratio = 1.